MYCOPHENOLATE MOFETIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mycophenolate Mofetil Hydrochloride, and what generic alternatives are available?
Mycophenolate Mofetil Hydrochloride is a drug marketed by Amneal, Bpi Labs, Endo Operations, Meitheal, Mylan Labs Ltd, Rising, Steriscience Speclts, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in MYCOPHENOLATE MOFETIL HYDROCHLORIDE is mycophenolate mofetil hydrochloride. There are thirty-eight drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the mycophenolate mofetil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mycophenolate Mofetil Hydrochloride
A generic version of MYCOPHENOLATE MOFETIL HYDROCHLORIDE was approved as mycophenolate mofetil hydrochloride by ENDO OPERATIONS on October 28th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYCOPHENOLATE MOFETIL HYDROCHLORIDE?
- What are the global sales for MYCOPHENOLATE MOFETIL HYDROCHLORIDE?
- What is Average Wholesale Price for MYCOPHENOLATE MOFETIL HYDROCHLORIDE?
Summary for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 10 |
Raw Ingredient (Bulk) Api Vendors: | 25 |
Clinical Trials: | 954 |
Patent Applications: | 137 |
DailyMed Link: | MYCOPHENOLATE MOFETIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fred Hutchinson Cancer Center | Phase 2 |
National Cord Blood Network | Phase 2 |
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | Phase 1 |
Pharmacology for MYCOPHENOLATE MOFETIL HYDROCHLORIDE
Drug Class | Antimetabolite Immunosuppressant |